#1 Clinical Trials Search in Europe

CHLOROQUINE PHOSPHATE

Chloroquine phosphate has a long history in medicine, primarily known for its use in treating malaria. However, recent clinical trials have been exploring its potential applications in a wider range of conditions. This article examines how chloroquine phosphate is being used in various clinical trials, from its traditional role in malaria treatment to emerging applications in conditions such as COVID-19, autoimmune diseases, and even cancer. By reviewing current research, we can better understand the versatility of this medication and its potential benefits and limitations across different medical contexts.

# Chloroquine Phosphate: A Comprehensive Guide for Patients Table of Contents – [What is Chloroquine Phosphate?](#what-is-chloroquine-phosphate) – [Medical Uses](#medical-uses) – [How Chloroquine Works](#how-chloroquine-works) – [Dosage and Administration](#dosage-and-administration) – [Side Effects and Safety Concerns](#side-effects-and-safety-concerns) – [Drug Interactions](#drug-interactions) – [Special Populations](#special-populations) – [COVID-19 Research](#covid-19-research) – [Current Research and Future Applications](#current-research-and-future-applications) What is Chloroquine Phosphate? Chloroquine phosphate is a medication that has been used for over 70 years in various medical applications. It belongs to the class of drugs known as 4-aminoquinolines, which are synthetic derivatives of quinine, a compound originally extracted from the bark of the Cinchona tree [1]. Chloroquine is available in tablet form, with each tablet typically containing 250 mg of chloroquine phosphate (equivalent to 150 mg of chloroquine base). Common brand names for chloroquine phosphate include Aralen, Chloroquine, and Plasmodín. In some regions, the drug may also be known as Chloroquine diphosphate or A-CQ [2]. Medical Uses Chloroquine phosphate has several established medical uses, with the most significant applications including: # Malaria Treatment and Prevention Chloroquine has been widely used since 1946 for both treatment and prevention (prophylaxis) of malaria [3]. It is particularly effective against certain types of the malaria parasite, including: – Plasmodium vivax – Plasmodium malariae – Plasmodium ovale – Susceptible strains of Plasmodium falciparum For uncomplicated malaria, chloroquine is typically administered as a 3-day regimen with a total dose of 25 mg/kg body weight [4]. However, due to increasing resistance of Plasmodium falciparum to chloroquine in many parts of the world, its use has been limited in regions where resistant strains are common. # Autoimmune Diseases Chloroquine has anti-inflammatory properties that make it useful in treating certain autoimmune conditions [1], including: – Autoimmune hepatitis – Systemic lupus erythematosus – Rheumatoid arthritis In these conditions, chloroquine helps reduce inflammation and modify the immune system’s response. For autoimmune hepatitis, studies have shown that chloroquine can help maintain remission after withdrawal of standard treatments [1]. # Other Medical Uses Research has explored additional applications for chloroquine, including: – Treatment of viral infections – Atrial fibrillation management – Cancer therapy adjuvant How Chloroquine Works Chloroquine’s mechanisms of action vary depending on the condition being treated: # Antimalarial Action As an antimalarial agent, chloroquine: – Accumulates in the acidic food vacuoles of malaria parasites – Increases the pH within these vacuoles – Interferes with the parasite’s ability to digest hemoglobin – Disrupts the parasite’s metabolism and reproduction [1] # Anti-inflammatory and Immunomodulatory Effects In autoimmune conditions, chloroquine: – Inhibits the release of tumor necrosis factor (TNF) from mononuclear phagocytes – Down-regulates TNF receptors by delaying their transport to the cell surface – Alters membrane permeability and lysosomal function – Accumulates in tissues in considerable amounts (200-700 times the plasma concentration can be found in liver, spleen, kidneys, and lungs) [1] # Antiviral Effects Some research suggests chloroquine may have antiviral properties by: – Interfering with virus entry into cells – Altering the pH of endosomes needed for virus entry – Interfering with post-translational modification of viral proteins [5] Dosage and Administration Chloroquine dosage varies significantly based on the condition being treated, the patient’s weight, and other factors. Always follow your healthcare provider’s specific instructions. # For Malaria Treatment The standard adult dosage for treating uncomplicated malaria is typically: – Day 1: 10 mg/kg body weight (usually 4 tablets for adults) – Day 2: 10 mg/kg body weight (4 tablets) – Day 3: 5 mg/kg body weight (2 tablets) [4] For children or adults under 60 kg, the dosage is adjusted based on weight. # For Malaria Prevention For prophylaxis (prevention) in areas with chloroquine-sensitive malaria: – Adults: 500 mg (300 mg base) once weekly – Start 1-2 weeks before travel to endemic areas – Continue during travel and for 4 weeks after leaving the area [6] # For Autoimmune Conditions For conditions like autoimmune hepatitis: – Typical dose is 250 mg daily [1] – Treatment duration depends on the specific condition and response Side Effects and Safety Concerns While chloroquine is generally considered safe when used as directed, it can cause various side effects ranging from mild to severe. # Common Side Effects Mild and transient side effects may include: – Gastrointestinal symptoms (nausea, vomiting, diarrhea) – Headache – Dizziness – Blurry vision – Fatigue [1] # Serious Side Effects More severe reactions that require immediate medical attention include: – Eye injuries (retinopathy, changes to the retina, lens, cornea, or optic nerve) – Cardiovascular manifestations (heart rhythm abnormalities) – Neuromuscular disorders – Hearing loss – Severe skin reactions [1] # Ocular Toxicity One of the most concerning adverse effects of chloroquine is retinal damage, which can occur with long-term use. This risk increases with: – Higher daily doses (exceeding 250 mg of chloroquine phosphate) – Longer duration of treatment – Pre-existing eye conditions – Kidney or liver disease [1] To minimize this risk, regular ophthalmologic examinations (every 4-6 months) are recommended for patients on long-term chloroquine therapy. # QT Interval Prolongation Chloroquine can prolong the QT interval on electrocardiogram (ECG), potentially leading to serious cardiac arrhythmias. This risk is higher in patients with: – Pre-existing heart conditions – Electrolyte imbalances – Concurrent use of other QT-prolonging medications [7] Drug Interactions Chloroquine can interact with various medications, potentially increasing the risk of side effects or reducing effectiveness. # Significant Interactions – Antacids and kaolin: May reduce absorption of chloroquine – Ampicillin: Chloroquine may reduce its absorption – Cyclosporine: Chloroquine may increase blood levels – Digoxin: Chloroquine may increase digoxin levels – QT-prolonging drugs: Increased risk of cardiac arrhythmias – Mefloquine: Increased risk of seizures [1] Special Populations # Pregnancy and Breastfeeding Chloroquine is considered relatively safe during pregnancy, particularly for malaria treatment and prevention. It has been widely used for decades in pregnant women with no evidence of significant harm to the fetus [8]. Chloroquine is also considered safe during breastfeeding, as the amount excreted in breast milk is not sufficient to harm the infant. # G6PD Deficiency Unlike primaquine, chloroquine is generally considered safe for patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. In fact, chloroquine is often used as an alternative treatment in these patients when primaquine is contraindicated [7]. # Children Chloroquine can be used in children, with dosage adjusted based on weight. However, children may be more sensitive to chloroquine toxicity, so careful dosing is essential [9]. # Elderly Older adults may be more sensitive to the effects of chloroquine and may require dosage adjustments. They are also at higher risk for side effects, particularly retinal toxicity and cardiac effects [10]. COVID-19 Research During the COVID-19 pandemic, chloroquine was investigated as a potential treatment for SARS-CoV-2 infection. Early laboratory studies suggested that chloroquine might inhibit virus entry into cells and reduce viral replication [5]. Several clinical trials were conducted to evaluate the efficacy and safety of chloroquine in COVID-19 patients, including: – A multi-center, randomized, open-label trial in Vietnam to evaluate the safety and efficacy of chloroquine in hospitalized adults with confirmed SARS-CoV-2 infection [11] – A trial in Poland examining chloroquine’s potential role in reducing COVID-19-related hospitalization or death in ambulatory patients [5] – Studies evaluating chloroquine as prophylaxis for healthcare workers exposed to COVID-19 patients [12] However, subsequent larger clinical trials did not demonstrate significant benefits for COVID-19 treatment, and concerns about potential cardiac toxicity led most medical authorities to recommend against its use for this indication outside of clinical trials [13]. Current Research and Future Applications Research continues to explore new potential applications for chloroquine: # Cancer Treatment Studies are investigating chloroquine’s potential as an adjunct to cancer therapy. It may enhance the effectiveness of certain chemotherapy drugs by inhibiting autophagy (a cellular process that cancer cells can use to survive treatment) [14]. # Atrial Fibrillation Early research is examining whether chloroquine could help terminate persistent atrial fibrillation, potentially offering a new pharmacological approach to managing this common heart rhythm disorder [15]. # HIV Infection Some studies have explored chloroquine’s ability to modulate T-cell immune activation in HIV-infected individuals. It may help improve CD4 T-cell recovery in patients receiving antiretroviral therapy [16]. # Influenza Prevention Research has evaluated chloroquine’s potential for preventing influenza infection, though results have been mixed [17]. As with any medication, it’s important to use chloroquine only as prescribed by your healthcare provider. Regular monitoring is essential, particularly for patients on long-term therapy, to detect and manage potential side effects early.
Application Area Trial Examples Dosing Approach Key Findings/Status
COVID-19 Treatment WROCLAW CORONA STUDY 2020, Vietnam Chloroquine Treatment Trial Various regimens: 500mg twice daily for initial days followed by maintenance dosing Studies explored efficacy in reducing hospitalization/death and viral clearance time. Results mixed, not currently standard of care.
Malaria Treatment Multiple trials for P. vivax and P. falciparum infections Standard: 25mg/kg total dose over 3 days (10mg/kg day 1, 10mg/kg day 2, 5mg/kg day 3) Still effective in many regions, often combined with primaquine for P. vivax to prevent relapse. Some areas showing resistance.
Autoimmune Conditions Trials for autoimmune hepatitis maintenance therapy 250mg/day for maintenance therapy May help maintain remission after withdrawal of conventional immunosuppressants, with fewer side effects than long-term steroids.
Cardiovascular Applications Trial for persistent atrial fibrillation 500mg daily for 2 days, then 250mg daily for 12 days Exploring potential to terminate persistent atrial fibrillation and reduce recurrence.
HIV Treatment Support Chloroquine as modulator of T cell immune activation 250mg daily for 24 weeks Investigation of effects on immune activation and CD4 recovery in HIV patients on antiretroviral therapy.
Cancer Therapy Combination with carboplatin/gemcitabine in advanced solid tumors Dose escalation: 50mg to 200mg daily Exploring anti-autophagy effects to enhance chemotherapy efficacy in cancer treatment.
Malaria Prevention Preventive trials in healthcare workers and endemic populations Weekly or biweekly dosing regimens Evaluation of prophylactic potential, particularly in healthcare workers exposed to infectious diseases.
Special Populations Pharmacokinetics in pregnancy, G6PD deficiency studies Standard therapeutic doses with careful monitoring Important considerations for safety in pregnant women and those with G6PD deficiency who require malaria treatment.

FAQ

  • What is chloroquine phosphate? Chloroquine phosphate is a medication that belongs to the 4-aminoquinoline class of drugs. It was originally developed to treat malaria and has been used for this purpose for over 70 years. Each tablet typically contains 250mg of chloroquine phosphate, which is equivalent to 150mg of chloroquine base. The drug works by interfering with parasite growth and replication in red blood cells and has anti-inflammatory properties that make it useful for treating certain autoimmune conditions as well.
  • How is chloroquine phosphate being used in COVID-19 treatment? Several clinical trials have investigated chloroquine phosphate as a potential treatment for COVID-19. For example, in the 'WROCLAW CORONA STUDY 2020,' researchers evaluated whether chloroquine phosphate combined with telemedicine care could reduce COVID-19-related hospitalization or death in ambulatory patients. The Vietnam Chloroquine Treatment trial assessed its safety and efficacy in hospitalized adults with laboratory-confirmed SARS-CoV-2 infection. These studies were based on laboratory evidence suggesting chloroquine might inhibit virus entry into cells. However, results have been mixed, and chloroquine is not currently recommended as a standard treatment for COVID-19.
  • What are the common side effects of chloroquine phosphate? Common side effects of chloroquine phosphate include gastrointestinal symptoms (such as nausea, vomiting, stomach pain, and diarrhea), headache, dizziness, blurry vision, and fatigue. More serious but less common side effects can include skin rashes, itching, cardiovascular manifestations, eye injuries (particularly with long-term use), neuromuscular disorders, and hearing loss. Regular ophthalmologic examinations are recommended for patients on long-term treatment to monitor for retinal damage, which can occur with prolonged use.
  • Can chloroquine phosphate be used for conditions other than malaria? Yes, clinical trials are exploring the use of chloroquine phosphate for various conditions beyond malaria. It's being studied for autoimmune hepatitis maintenance therapy, atrial fibrillation treatment, as an anti-cancer agent in combination with other therapies, and as an immune modulator in HIV infection. The drug's anti-inflammatory and immunomodulatory properties make it potentially useful for conditions where inflammation plays a role. However, these applications are still being researched, and chloroquine should only be used for non-malaria conditions under appropriate medical supervision.
  • How is chloroquine phosphate administered in malaria treatment? For malaria treatment, chloroquine phosphate is typically administered orally over three days. The standard adult dosage is about 1000mg (10mg/kg) on the first day, followed by 500mg (5mg/kg) on the second and third days, for a total dose of 25mg/kg. In some trials, it's used in combination with primaquine for the complete elimination of Plasmodium vivax malaria, where primaquine targets the liver stage parasites to prevent relapse. Dosing may be adjusted based on the patient's weight, and the medication is often given with food to reduce gastrointestinal side effects.

Ongoing Clinical Trials on CHLOROQUINE PHOSPHATE

  • Study on the Long-Term Safety of Dazukibart in Patients with Idiopathic Inflammatory Myopathies, Including Dermatomyositis and Polymyositis

    Recruiting

    1 1 1 1
    Investigated drugs:
    Bulgaria Hungary Italy Poland Spain Sweden

  • Study on the Effectiveness of Dazukibart in Adults with Active Dermatomyositis or Polymyositis

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria France Germany Hungary Italy +4

Glossary

  • Chloroquine Phosphate: An antimalarial and anti-inflammatory medication that works by inhibiting parasite growth in red blood cells and modulating immune responses. Each 250mg tablet contains approximately 150mg of chloroquine base.
  • Plasmodium vivax: A species of parasitic protozoa that causes a form of malaria in humans. It can remain dormant in the liver as hypnozoites, causing relapses of the disease weeks to months after the initial infection.
  • Plasmodium falciparum: The most severe form of malaria parasite and the most likely to cause fatal infections. Unlike P. vivax, it does not remain dormant in the liver but can rapidly multiply in the bloodstream.
  • Primaquine: An antimalarial medication specifically used to eliminate the liver stage (hypnozoites) of Plasmodium vivax parasites to prevent relapses. Often administered after chloroquine treatment.
  • G6PD Deficiency: Glucose-6-phosphate dehydrogenase deficiency, a genetic disorder that can cause red blood cells to break down (hemolysis) when certain medications, including primaquine, are taken. Testing for G6PD deficiency is important before administering primaquine.
  • Therapeutic Failure: The inability of a treatment to clear infection or prevent recurrence. In malaria treatment, this may be classified as early treatment failure (within first 3 days) or late treatment failure.
  • Adequate Clinical and Parasitological Response (ACPR): The absence of parasitemia (parasites in the blood) on the final day of follow-up without previously meeting any criteria of treatment failure. This indicates successful treatment.
  • Recrudescence: The return of symptoms after a period of improvement, due to the survival of some parasites after treatment, rather than a new infection.
  • Relapse: The return of malaria symptoms due to activation of dormant liver-stage parasites (hypnozoites) of Plasmodium vivax, rather than failed treatment of blood-stage parasites.
  • PfSPZ Challenge: A preparation of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites used in malaria vaccine development and controlled human malaria infection studies.
  • Chemoprophylaxis: The use of medication to prevent disease. In malaria, chloroquine can be used as chemoprophylaxis to prevent infection in individuals traveling to areas where malaria is endemic.
  • Controlled Human Malaria Infection (CHMI): A research approach where healthy volunteers are deliberately infected with malaria parasites under controlled conditions to study immune responses or test interventions.
  • SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2, the virus that causes COVID-19 (Coronavirus Disease 2019).
  • Autophagy: A cellular process where cells degrade and recycle their components. Chloroquine can inhibit autophagy, which may have applications in cancer treatment.
  • Unfolded Protein Response (UPR): A cellular stress response related to the endoplasmic reticulum, which can be targeted in cancer treatment approaches.

References

  1. https://clinicaltrials.gov/study/NCT01980745
  2. https://clinicaltrials.gov/study/NCT04344951
  3. https://clinicaltrials.gov/study/NCT03083847
  4. https://clinicaltrials.gov/study/NCT02691910
  5. https://clinicaltrials.gov/study/NCT04331600
  6. https://clinicaltrials.gov/study/NCT02698748
  7. https://clinicaltrials.gov/study/NCT03529396
  8. https://clinicaltrials.gov/study/NCT01546961
  9. https://clinicaltrials.gov/study/NCT06044805
  10. https://clinicaltrials.gov/study/NCT04341727
  11. https://clinicaltrials.gov/study/NCT04328493
  12. https://clinicaltrials.gov/study/NCT04443270
  13. https://clinicaltrials.gov/study/NCT04627467
  14. https://clinicaltrials.gov/study/NCT02071537
  15. https://clinicaltrials.gov/study/NCT02932007
  16. https://clinicaltrials.gov/study/NCT00308620
  17. https://clinicaltrials.gov/study/NCT01078779